Genzyme plans non-core exits and share buyback; urges shareholders to snub Icahn
This article was originally published in Scrip
Executive Summary
Genzyme has laid out plans to exit three non-core business areas and buy back $2 billion of stock as chairman and CEO Henri Termeer continues to do battle against activist shareholder Carl Icahn.